Stay updated on Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial
Sign up to get notified when there's something new on the Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial page.

Latest updates to the Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial page
- CheckyesterdayChange DetectedThe displayed site revision changed from v3.8.0 to v3.8.1, reflecting a website version update rather than a change to the clinical trial record.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe study record for perioperative mFOLFOX and pembrolizumab in potentially resectable gastroesophageal junction and stomach adenocarcinoma is displayed, including its design, eligibility criteria, treatment regimen, and outcome measures.SummaryDifference51%

- Check22 days agoChange DetectedThe footer revision marker changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA notice about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the existing 403 error page.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check43 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page; its footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Periop mFOLFOX + Pembrolizumab in GEJ & Stomach Clinical Trial page.